Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 25:8:567659.
doi: 10.3389/fcell.2020.567659. eCollection 2020.

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis

Hernan Inojosa  1 , Judith Eisele  1 , Undine Proschmann  1 , Sebastian Zeissig  2 , Katja Akgün  1 , Tjalf Ziemssen  1
Affiliations

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis

Hernan Inojosa et al. Front Cell Dev Biol. .

Abstract

Background: Fingolimod (FTY) is a sphingosine 1 phosphate (S1P) agonist with significant effects on immune cell distribution used as an effective disease modifying therapy in multiple sclerosis (MS) patients. Animal studies have demonstrated that a dysregulation of egress of murine secretory Immunglobulin A (sIgA)+ plasmablasts from Peyer's patches in FTY-treated mice reduced fecal sIgA levels. Alterations in intestinal levels of sIgA could modify the gut microbiome and homeostasis in humans. We analyzed the effect of FTY on the fecal and salivary sIgA levels as marker of the humoral immune system in the gut.

Methods: Twenty five people with confirmed MS diagnosis according to 2010 revised McDonald's criteria and on long-term continuous treatment at the MS Center in Dresden, Germany were enrolled in this exploratory cross-sectional study. Fecal and salivary sIgA were analyzed after at least 12 months of treatment with FTY or Glatiramer acetate (GA).

Results: Fifteen MS patients on FTY and 10 on GA participated in this study. The mean fecal sIgA concentration of both groups was not decreased compared to reference values and did not demonstrate significant differences between them (FTY 3323.13 μg/g +/- 2094.72; GA 2040.65 μg/g +/- 1709.07). A similar pattern was seen in the salivary sIgA and serum immunoglobulins levels.

Conclusion: In this pilot study, we could not confirm the decrease of fecal sIgA after a long-term treatment with FTY. Further longitudinal studies should evaluate the effects of MS treatments on the gut immune system in more detail.

Keywords: fingolimod; gut immune system; microbiome; multiple sclerosis; sIgA; secretory immunglobulin A.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Blaho V. A., Hla T. (2014). An update on the biology of sphingosine 1-phosphate receptors. J. Lipid Res. 55 1596–1608. 10.1194/jlr.R046300 - DOI - PMC - PubMed
    1. Boullier S., Tanguy M., Kadaoui K. A., Caubet C., Sansonetti P., Corthesy B., et al. (2009). Secretory IgA-mediated neutralization of Shigella flexneri prevents intestinal tissue destruction by down-regulating inflammatory circuits. J. Immunol. 183 5879–5885. 10.4049/jimmunol.0901838 - DOI - PubMed
    1. Brandtzaeg P. (2009). Mucosal immunity: induction, dissemination, and effector functions. Scand. J. Immunol. 70 505–515. 10.1111/j.1365-3083.2009.02319.x - DOI - PubMed
    1. Brandtzaeg P. (2013). Secretory IgA: designed for anti-microbial defense. Front. Immunol. 4:222. 10.3389/fimmu.2017.00222 - DOI - PMC - PubMed
    1. Brinkmann V., Billich A., Baumruker T., Heining P., Schmouder R., Francis G., et al. (2010). Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9 883–897. 10.1038/nrd3248 - DOI - PubMed

LinkOut - more resources